HORIZON
A randomized double-blind, placebo-controlled, multicenter study assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease
- Stage
- followup
- Medicine
- TQJ230
- Population
- ASCVD
- Phase
- III
- First Patient In
- 13 May 2020
- Last Patient In
- 8 July 2022
- Last Patient Last Visit
- 31 March 2026
National Lead
prof. dr. E.S.G. Stroes
Cardioloog
Study Director
